GSK, GlycoVaxyn collaborate on bacterial vaccine development

12/20/2012 | Genetic Engineering & Biotechnology News

GlaxoSmithKline Biologicals and GlycoVaxyn agreed to use the latter's bioconjugation technology to develop novel bacterial vaccines. The deal, which covers a set of pathogen targets, gives GSK an exclusive licensing option. GSK will give GlycoVaxyn an upfront payment and equity investment plus milestone fees and royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD